Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) announced its earnings results on Thursday. The real estate investment trust reported $0.11 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.28), FiscalAI reports. Sabra Healthcare REIT had a return on equity of 6.38% and a net margin of 23.50%.The business had revenue of $201.35 million during the quarter, compared to analyst estimates of $201.97 million. Sabra Healthcare REIT updated its FY 2026 guidance to 1.550-1.590 EPS.
Sabra Healthcare REIT Price Performance
Shares of NASDAQ:SBRA traded up $0.65 during trading on Thursday, hitting $20.25. 5,080,902 shares of the company were exchanged, compared to its average volume of 2,810,294. Sabra Healthcare REIT has a 1-year low of $15.60 and a 1-year high of $20.27. The company has a market capitalization of $5.05 billion, a P/E ratio of 28.13 and a beta of 0.67. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.92. The business’s 50 day moving average is $19.00 and its 200-day moving average is $18.74.
Sabra Healthcare REIT Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 27th. Investors of record on Friday, February 13th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date is Friday, February 13th. Sabra Healthcare REIT’s dividend payout ratio is currently 166.67%.
Institutional Trading of Sabra Healthcare REIT
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on SBRA shares. National Bank Financial set a $22.00 target price on shares of Sabra Healthcare REIT in a research report on Friday, October 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $22.00 price objective on shares of Sabra Healthcare REIT in a research report on Monday, December 15th. UBS Group assumed coverage on shares of Sabra Healthcare REIT in a research note on Tuesday, November 18th. They set a “neutral” rating and a $20.00 price objective for the company. Wall Street Zen downgraded shares of Sabra Healthcare REIT from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Finally, Truist Financial upped their price target on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Tuesday, January 20th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Sabra Healthcare REIT presently has a consensus rating of “Hold” and an average price target of $21.11.
View Our Latest Report on Sabra Healthcare REIT
About Sabra Healthcare REIT
Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.
Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.
Further Reading
- Five stocks we like better than Sabra Healthcare REIT
- USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.
- My Epstein Story
- When to buy gold (mathematically)
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Trump’s AI Secret: 100X Faster Than Nvidia
Receive News & Ratings for Sabra Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
